196 related articles for article (PubMed ID: 26170629)
21. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
Bajaj M; Heath EI
Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
[TBL] [Abstract][Full Text] [Related]
22. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
23. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
24. Siltuximab in transplant-ineligible patients with myeloma.
Bagcchi S
Lancet Oncol; 2014 Jul; 15(8):e309. PubMed ID: 25121174
[No Abstract] [Full Text] [Related]
25. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract][Full Text] [Related]
26. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice.
Zaki MH; Nemeth JA; Trikha M
Int J Cancer; 2004 Sep; 111(4):592-5. PubMed ID: 15239138
[TBL] [Abstract][Full Text] [Related]
27. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J; Aird G; Ahmed A; Silberstein PT
Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
[TBL] [Abstract][Full Text] [Related]
28. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
30. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
[TBL] [Abstract][Full Text] [Related]
31. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
[TBL] [Abstract][Full Text] [Related]
32. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
[No Abstract] [Full Text] [Related]
33. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies and side-effect management.
Muehlbauer PM; Cusack G; Morris JC
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):11-21; discussion 22-3. PubMed ID: 18153975
[TBL] [Abstract][Full Text] [Related]
35. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
[TBL] [Abstract][Full Text] [Related]
36. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
37. A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.
Villaescusa L; Zaragozá F; Gayo-Abeleira I; Zaragozá C
Adv Ther; 2022 Mar; 39(3):1126-1148. PubMed ID: 35072887
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
39. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
40. Siltuximab: first global approval.
Markham A; Patel T
Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
